Stroke

Partnership to develop and market Desmoteplase

Published in Drug Week, August 12th, 2005

PAION Deutschland GmbH and H. Lundbeck A/S announced that they have entered into an exclusive partnership agreement for the development and marketing of PAION's phase III product Desmoteplase for stroke in Europe, Japan and the rest of the world except the United States (USA) and Canada.

Forest Laboratories holds the marketing and development rights in the USA and Canada.

Desmoteplase, a novel plasminogen activator, or blood clot-dissolving agent, has the potential to treat patients with acute ischaemic stroke up to 9 hours after onset of symptoms. Ischaemic stroke is the most common type of stroke and occurs when an artery in the brain is obstructed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-08-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry